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Introduction
Cancer cells exhibit many properties that have been shown to 
cause apoptosis in normal cells. Among these is the activation 
of proliferative oncoproteins like MYC. Activation of MYC in-
duces a transcriptional program that can result in increased pro-
liferation, but often at the expense of cell death via the apoptotic 
pathway. Whether the net effect is increased proliferation or 
apoptosis appears to vary depending on cell context. Conditions 
which often occur in cancer, such as growth factor and/or   
oxygen deprivation, can sensitize MYC-expressing cells to apop-
tosis (Evan et al., 1992; Graeber et al., 1996; Brunelle et al., 
2004). To survive in these conditions, the cells must find a way 
to prevent cell death. Cancer cells can select for ways to block 
the apoptotic signaling from MYC in order to tip the balance in 
favor of proliferation. A seminal observation of this principle 
was made when it was found that overexpression of the anti-
apoptotic protein BCL-2 (B cell leukemia/lymphoma 2) could 
rescue cells from MYC-induced apoptosis (Bissonnette et al., 
1992; Fanidi et al., 1992). However, the molecular mechanisms 
responsible for the apoptotic induction by MYC and its rescue 
by BCL-2 remain incompletely understood.
The BCL-2 family proteins control apoptosis at the mito-
chondrion. They are related by sequence homology and by par-
ticipation in control of apoptosis (Danial and Korsmeyer, 2004). 
They contain one or more BCL-2 homology (BH) domains that 
are involved in protein–protein interactions. BCL-2 family pro-
teins containing only a BH3 domain can be activated in response 
to critical aberrations in cellular physiology, including DNA 
damage, growth factor withdrawal, and oncogene activation 
(Puthalakath and Strasser, 2002). These BH3-only proteins are 
activated by mechanisms involving transcriptional up-regulation, 
subcellular localization, and/or posttranslational modification. 
In one model of apoptotic control, the so-called “direct” model, 
certain BH3-only proteins (including BID, BIM, and perhaps 
PUMA) are known as “activators.” These proteins activate the 
pro-apoptotic BCL-2 family proteins BAX and BAK (Wei et al., 
2000; Certo et al., 2006; Letai, 2008). Activated BAX and BAK 
then homo-oligomerize and cooperate in the permeabilization 
of the outer mitochondrial membrane. Pro-apoptotic contents of 
the mitochondrial intermembrane space, including cytochrome c, 
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apoptotic proteins in the BCL-2 protein family 
often  expressed  in  cancer.  To  compare  the  function  of 
MCL-1 and BCL-2 in maintaining cancer survival, we con-
structed complementary mouse leukemia models based 
on E-Myc expression in which either BCL-2 or MCL-1 
are required for leukemia maintenance. We show that 
the principal anti-apoptotic mechanism of both BCL-2 
and MCL-1 in these leukemias is to sequester pro-death 
BH3-only proteins rather than BAX and BAK. We find that 
the MCL-1–dependent leukemias are more sensitive to a 
wide range of chemotherapeutic agents acting by disparate 
mechanisms. In common across these varied treatments is 
that MCL-1 protein levels rapidly decrease in a proteosome-
dependent fashion, whereas those of BCL-2 are stable. 
We demonstrate for the first time that two anti-apoptotic 
proteins can enable tumorigenesis equally well, but none-
theless differ in their influence on chemosensitivity.
MCL-1–dependent leukemia cells are  
more sensitive to chemotherapy than  
BCL-2–dependent counterparts
Joslyn K. Brunelle,
1 Jeremy Ryan,
1 Derek Yecies,
1 Joseph T. Opferman,
2 and Anthony Letai
1
1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02052
2Department of Biochemistry, St. Jude Children’s Research Hospital, Memphis, TN 38105
©  2009  Brunelle  et  al.  This  article  is  distributed  under  the  terms  of  an  Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publica-
tion date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 187 • NUMBER 3 • 2009   430
been implicated in both tumorigenesis and chemoresistance, 
there is little known about MCL-1 dependence in cancer. There 
is evidence that MCL-1 is important for survival of myeloma 
cells, but the mechanism behind this requirement is obscure 
(Derenne et al., 2002). An MCL-1 transgenic murine model ex-
ists that demonstrates an increased risk of lymphoma, but the 
long latency (>18 mo on average) renders such a model incon-
venient for mechanistic studies (Zhou et al., 2001). In murine 
bone marrow viral infection models, MCL-1 was found to ac-
celerate both myeloid and lymphoid malignancies (Wendel   
et al., 2007; Beverly and Varmus, 2009).
To better understand MCL-1 dependence in cancer, we 
compared MCL-1– and BCL-2–dependent leukemia models. 
We find that BH3 profiling confirms the dependence in these 
tumors, and that the molecular basis to the dependence involves 
binding of BH3-only proteins rather than BAX or BAK. Fur-
thermore, we find that MCL-1–dependent leukemias are more 
sensitive to a wide variety of treatments than are their BCL-2–
dependent counterparts.
Results
MCL-1 facilitates myc-mediated 
leukemogenesis
It has been established previously that targeting Bcl-2 expres-
sion in mice to lymphoid cells that also overexpress the c-myc 
oncogene  results  in  rapid  onset  of  a  lymphoid  leukemia   
(Strasser et al., 1990). This leukemia is less mature and more 
rapidly fatal than the lymphoma generated by the c-myc onco-
gene alone (Adams et al., 1985). By using a Bcl-2 promoter that 
could be turned off when doxycycline was added to the drinking 
water, we showed that the resulting leukemia was explicitly de-
pendent on BCL-2 for survival (Letai et al., 2004). An important 
question remains whether other BCL-2 family anti-apoptotic 
transgenes could function similarly to facilitate lymphoid   
leukemogenesis driven by c-Myc in this transgenic model. To test 
whether MCL-1 overexpression results in a leukemia, the H2K 
promoter was used to target MCL-1 expression to many tissues, 
including blood, spleen, bone marrow, thymus, and lymph nodes. 
As expected, MCL-1 protein levels were significantly increased 
in spleen and bone marrow samples of H2K-Mcl-1 mice when 
compared with those of wild-type mice (Fig. 1 A). H2K-Mcl-1 
mice were crossed with E-Myc mice and a cohort was ana-
lyzed, henceforth called Mcl-1/E-Myc mice. Mcl-1/E-Myc 
mice survived only an average of 72 ± 21 d. Mice bearing the 
E-Myc transgene survived an average of 134 ± 35 d, whereas 
both mice bearing only the H2K-Mcl-1 transgene and wild-type 
mice survived well beyond 200 d (Fig. 1 B).
Given the results from prior models noted above, we sus-
pected that the early mortality in the Mcl-1/E-Myc mice was 
due to the development of a lymphoid leukemia. White blood cell 
counts for 4–6-wk-old Mcl-1/ E-Myc mice averaged 367,000 ± 
156,000 per microliter of blood. Counts from E-Myc only, 
H2K-Mcl-1 only, and wild-type mice of the same age were sig-
nificantly lower and nearly normal: 12,000 ± 2,000, 12,000 ± 
3,000, and 7,900 ± 1,600 per microliter of blood, respectively 
(Fig. 1 C). White blood cells isolated from Mcl-1/ E-Myc mice 
are released to the cytosol. These contents drive the activa-
tion of caspases, which are proteases that cleave and disable 
critical proteins throughout the cell. Anti-apoptotic proteins 
(BCL-2, MCL-1, BCL-XL, BFL-1, BCL-w) inhibit cell death 
by  intercepting  activator  BH3-only  proteins  and  preventing 
their interaction with BAX and BAK (Cheng et al., 1996; Certo 
et al., 2006). Anti-apoptotic proteins may also bind activated, 
monomeric BAX and BAK before they can oligomerize (Willis 
et al., 2005).
Other BH3-only proteins called sensitizers (including BAD, 
NOXA, and BIK) cannot activate BAX and BAK directly (Letai 
et al., 2002; Certo et al., 2006). Sensitizers promote death by 
displacing activators from the hydrophobic binding pocket of 
anti-apoptotic proteins. PUMA is a pro-apoptotic BH3-only 
protein first identified as a transcriptional target of p53 (Nakano 
and Vousden, 2001). Whether PUMA acts primarily as a sensi-
tizer or an activator remains the subject of debate. An alterna-
tive model of apoptosis control, the so-called “indirect” model, 
holds that BAX and BAK are not activated by activator BH3-
only proteins. A key principle of this model is that the anti-
apoptotic function of proteins like BCL-2 resides solely in their 
binding to BAX and BAK (Willis et al., 2007).
Certain cancers depend upon BCL-2 for survival. Under-
standing the mechanism of this dependence not only provides 
information to guide therapeutic targeting of such dependence, 
but also provides important insights into the function of BCL-2 
(Deng et al., 2007; Letai, 2008). We have previously studied 
BCL-2–dependent cancers including human chronic lympho-
cytic leukemia (CLL), lymphoma cell lines, small cell lung can-
cer cell lines, and a murine lymphocytic leukemia (Certo et al., 
2006; Del Gaizo Moore et al., 2007; Deng et al., 2007). We have 
found that BCL-2 dependence can be identified in cancer cells 
using a strategy we call BH3 profiling (Certo et al., 2006; Letai, 
2008). The main principle of BH3 profiling is to quantify mito-
chondrial dysfunction after treatment with a panel of BH3 pep-
tides. This affords the opportunity to isolate the mitochondrial 
precondition as a contributor to subsequent death decisions. By 
treating with measured death signals, in the form of BH3 pep-
tides, we can identify mitochondria that more readily undergo 
apoptosis than others. Because anti-apoptotic proteins each have 
a distinct pattern of interaction with the BH3 peptides, the pat-
tern of response to individual BH3 domains can identify the 
anti-apoptotic protein required to maintain survival in a cell.
A common property of the BCL-2 protein in BCL-2– 
dependent cells is that it is largely bound to pro-apoptotic   
proteins, specifically activator BH3-only proteins like BIM 
(Del Gaizo Moore et al., 2007; Deng et al., 2007). We refer to 
cells in this state as “primed for death,” or more simply “primed.” 
These proteins can be displaced by competition with peptides 
derived from the BH3 domains of BH3-only proteins. Mito-
chondrial dysfunction ensues and its measurement is the read-
out for BH3 profiling. We have previously found that primed 
cells are more sensitive to chemotherapy than unprimed cells 
(Deng et al., 2007).
The  anti-apoptotic  MCL-1  (myeloid  cell  leukemia  se-
quence 1) protein is gaining attention as a potential therapeutic 
target in cancer (Reynolds et al., 1994). Although MCL-1 has 431 MCL-1 and BCL-2 differ in chemoprotection • Brunelle et al.
H2K-Mcl-1, E-Myc, or wild-type mice are essentially normal. 
These results show that MCL-1 facilitates c-MYC–driven leu-
kemogenesis in a manner clinically and morphologically indis-
tinguishable  from  BCL-2. The  bone  marrow  from  leukemic 
mice is, however, quite distinct from that of E-Myc mice.
BH3 profiling distinguishes MCL-1– and 
BCL-2–dependent leukemias
We have previously used BH3 profiling to detect dependence 
on individual anti-apoptotic family proteins in several systems 
(Certo et al., 2006; Del Gaizo Moore et al., 2007; Deng et al., 
2007). An important test of this technique is whether it can dis-
tinguish between dependence on two different anti-apoptotic 
proteins in primary cancer cells. Our murine leukemia models 
provided an ideally controlled test case for performance of BH3 
profiling. Briefly, mitochondria were isolated from the white 
blood cells of Mcl-1/E-Myc mice. The mitochondria were 
treated with peptides corresponding to the BH3 domain of sev-
eral BCL-2 family proteins: BIM, BID, BAD, BIK, NOXA A, 
NOXA B, HRK, BNIP3, PUMA, and BMF. After peptide treat-
ment, release of cytochrome c was measured. The resulting pro-
file showed high levels of cytochrome c release when treated 
with BIM, BID, NOXA, PUMA, and BMF peptides (Fig. 3 A). 
This matches fluorescence polarization data indicating that 
MCL-1 has high affinity for BH3 domains derived from BIM, 
BID, NOXA, PUMA, and BMF (Certo et al., 2006). This pat-
tern thus corresponds to one of MCL-1 dependence. We also 
performed BH3 profiling on leukemia cells derived from the 
leukemia in BCL-2/E-Myc mice. We had previously explicitly 
shown that these leukemias were BCL-2 dependent, as they 
vanished when BCL-2 was removed using the tet-off switch 
(Letai et al., 2004). The BH3 profile of BCL-2/E-Myc white 
blood cells shows high levels of cytochrome c release when 
treated with BIM, BID, BAD, PUMA, BMF (Fig. 3 D). This 
pattern is consistent with mitochondrial BCL-2 dependence and 
consistent with the cellular BCL-2 dependence already estab-
lished. Thus, using BH3 profiling we have verified that we have 
engineered two distinct models of murine leukemia, differing in 
that one model is dependent on BCL-2 and the other model is 
dependent on MCL-1. We detected no other difference between 
the two leukemia models. These results increase our confidence 
in the ability of BH3 profiling to make the subtle distinction be-
tween dependence on different anti-apoptotic proteins in pri-
mary cancer samples.
Although MCL-1– and BCL-2–dependent primary leuke-
mia models were identified, it is convenient to perform replicate 
experiments with the same cell over time and primary leukemia 
cells are not useful reagents for such work. Thus, we established 
cell lines, three from each genotype that spontaneously immor-
talized in culture from these primary leukemias. The BH3 pro-
files of these cell lines correspond to the BH3 profile from the 
primary leukemias (examples in Fig. 3, B and E). Therefore, the 
cell lines were validated as cancer cell line models of MCL-1 
and BCL-2 dependence.
The BH3 profiling in Fig. 3, A, B, D and E relies on the 
performance of a heavy membrane preparation that is enriched 
for mitochondria at the expense of lighter membranes like   
were positive for B220 and CD19, negative for CD4, IgG, IgM, 
and IgD, and variable for AA4.1 and CD43 (unpublished data). 
This pattern confirms their B lymphocyte origin. Their cell sur-
face marking corresponds to a pre- or pro-B cell, class C or D in 
the Hardy scheme (Hardy and Hayakawa, 2001), consistent with 
the majority of leukemias derived from previously reported com-
bination of BCL-2 and c-Myc (Letai et al., 2004). The earliest 
white blood cell counts were taken after weaning and genotyping. 
Therefore, Mcl-1/E-Myc mice show evidence of leukemia by   
4 wk of age and may well have leukemia even earlier.
Spleen and bone marrow samples from 1–3-mo-old Mcl-1/
E-Myc mice contained a monotonous population of lympho-
blasts crowding out the normal trilineage hematopoiesis, simi-
lar to the BCL-2/E-Myc marrow samples (Fig. 2). Note that 
the bone marrow and spleen populations of comparably aged 
Figure 1.  MCL-1 overexpression targeted to hematopoietic cells by the 
H2K promoter in conjunction with c-myc results in the development of leu-
kemia in mice. (A) Levels of MCL-1 protein expression in wild-type and 
H2K-Mcl-1 mouse spleenocytes. (B) Kaplan-Meier plot showing the survival 
in number of days for Mcl-1/E-Myc, H2K-Mcl-1 only, E-Myc only, and 
wild-type mice. This is from a cohort of mice containing seven of each 
genotype. (C) Number of white blood cells per l of blood from Mcl-1/
E-Myc, H2K-Mcl-1 only, E-Myc only, and wild-type mice. This is from a 
cohort of mice containing seven of each genotype.JCB • VOLUME 187 • NUMBER 3 • 2009   432
between MOMP measured by cytochrome c release and by 
JC1 by this method (unpublished data). Dependence on MCL-1 
and BCL-2 are again demonstrated. As expected, the Bad pep-
tide  caused  a  rapid  decrease  in  mitochondrial  membrane   
potential in the putatively Bcl-2–dependent cells (Fig. 3 F), 
whereas the Noxa-specific peptides (Noxa A and Bim 2A) 
caused a decrease in mitochondrial membrane potential in the 
putatively Mcl-1–dependent cells (Fig. 3 C). The results using 
whole cells confirm the initial BH3 profiling results obtained 
endoplasmic  reticulum.  However,  these  lighter  membranes 
can also harbor MCL-1 and BCL-2, albeit usually at lower 
quantities. To better test the contribution of MCL-1 and BCL-2 
at all membrane locations, we turned to a modification of BH3 
profiling using whole cells. In this modification, cells were 
permeabilized with low concentrations of digitonin to permit 
peptide access to the cell interior, and mitochondrial perme-
abilization was measured with the JC1 dye. We have found 
across dozens of cell lines that there is a tight correlation 
Figure 2.  Pathology reveals that the normal ar-
chitecture of spleen and bone marrow is replaced 
by a monotonous population of lymphoblasts in 
Mcl-1/E-Myc  mice,  similar  to  BCL-2/E-Myc 
mice. (A) Wildtype. (B) H2K-Mcl-1 only. (C) E-Myc 
only. (D) Mcl-1/E-Myc. (E) BCL-2/E-Myc. Bar 
for the spleen samples is 100 µm, and bar for the 
bone marrow samples is 50 µm.433 MCL-1 and BCL-2 differ in chemoprotection • Brunelle et al.
likely because the MCL-1 and BCL-2 are sequestering pro-
death molecules that would induce death if MCL-1 or BCL-2 
function were lost or abrogated. In this situation, we describe 
the pro-death proteins as “priming” MCL-1 or BCL-2, and cells 
or mitochondria or anti-apoptotic proteins in that situation to be 
“primed” (Certo et al., 2006; Deng et al., 2007). To determine 
what  pro-death  molecules  are  priming  MCL-1  in  Mcl-1/ 
E-Myc leukemia, coimmunoprecipitation was performed from 
CHAPS lysates of white blood cells from two primary samples 
and one cell line. MCL-1 did indeed coimmunoprecipitate with 
BIM and PUMA, but not with BID, BAX, or BAK (Fig. 4 A). 
Similar  to  the  Mcl-1/E-Myc  leukemia  and  to  prior  results   
(Letai et al., 2004), BCL-2/E-Myc white blood cell lysates 
show that BCL-2 coimmunoprecipitated with BIM and PUMA, 
but not BID, BAX, or BAK in two primary samples and one cell 
line (Fig. 4 B). In summary, it appears that anti-apoptotic pro-
teins BCL-2 and MCL-1 are primed with BH3-only proteins 
BIM and PUMA. In contrast, priming by BAX and BAK is not 
detectable. Others have found that BAK and MCL-1 interact, 
and we and others have found that BAX and BCL-2 interact in 
from isolated mitochondria. Results from all six cell lines can 
be seen in Fig. S1.
To further ensure that key apoptotic phenotypes were pre-
served, we treated the cell lines with doxycycline, which turns 
off BCL-2 expression and induces killing of leukemia cells in 
vivo. We found that doxycycline efficiently induced killing of 
BCL-2/E-Myc leukemia cell lines, but not Mcl-1/E-Myc leu-
kemia cell lines (Fig. 3 G). These cell lines provided us with a 
pair of models which differed only in whether they were depen-
dent on BCL-2 or MCL-1. We are unaware of any other compa-
rable pairing of primary or cancer cell line models contrasting 
defined BCL-2 and MCL-1 dependence. BH3 profiling demon-
strated a remarkable ability to distinguish these two models.
MCL-1 and BCL-2 are primed with  
pro-death BIM and PUMA
Anti-apoptotic  proteins  inhibit  apoptosis  by  binding  and  se-
questering  pro-apoptotic  BH3-only  proteins  and  possibly 
monomeric BAX or BAK, especially when BAX or BAK have 
been activated. If cells are dependent on MCL-1 or BCL-2, it is 
Figure 3.  BH3 profiling distinguishes BCL-2– 
and MCL-1–dependent leukemias. Each profile 
is an average and standard deviation of three 
independent experiments, except for the JC1 
whole-cell assay. The JC1 whole-cell assay is 
one experiment done in triplicate, with the av-
erage of the three repeats presented here. 
(A) BH3 profile of Mcl-1/E-Myc primary leu-
kemia cells. (B) BH3 profile of Mcl-1/E-Myc 
cell line. (C) BH3 profile of Mcl-1/E-Myc cell 
line using the JC1 whole-cell assay. (D) BH3 
profile  of  BCL-2/  E-Myc  primary  leukemia 
cells. (E) BH3 profile of BCL-2/E-Myc cell line. 
(F) BH3 profile of BCL-2/E-Myc cell line using 
the JC1 whole-cell assay. (G) Cell lines were 
treated with doxycycline for 7 d and survival 
assessed as the Annexin V negative popula-
tion, measured by FACS. Data presented are 
from a single experiment; the experiment was 
repeated twice.JCB • VOLUME 187 • NUMBER 3 • 2009   434
BH3 profiling. This technique shows that dependence on anti-
apoptotic proteins in these lymphomas varies from case to case. 
The lymphoma from mouse #859 demonstrates MCL-1 depen-
dence (Fig. 5 A). Combinations of BCL-2, BCL-XL, and/or 
MCL-1 dependence were discovered in the lymphomas of three 
other mice tested (Fig. 5, B–D). To test whether patterns of pro-
tein expression bore a discernable relationship to the depen-
dence observed in BH3 profiling, we examined immunoblots of 
whole-cell lysates of the lymphomas (Fig. 5 E). Consistent with 
the MCL-1 dependence seen by BH3 profiling, MCL-1 protein 
levels are high and BCL-2 protein levels are relatively lower 
in tumor #859 (Fig. 5 A). In the remaining lymphoma cells with 
a more mixed picture of dependence by BH3 profiling, expres-
sion of BCL-2, MCL-1, and BCL-XL appeared more mixed.   
In the absence of a transgene driving overexpression of a partic-
ular anti-apoptotic protein, c-MYC–driven lymphomas demon-
strate a heterogeneous pattern of dependence on anti-apoptotic 
proteins. It is a formal possibility that some of this heterogene-
ity might derive from oligo- or poly-clonality in the tumors. 
However, although we did not directly demonstrate clonality for 
the tumors studied here, others have shown that tumors from 
this model are almost always monoclonal (Adams et al., 1985).
Western blotting was also used to compare Bcl-2 family 
protein levels among BCL-2/E-Myc–, Mcl-1/E-Myc–, and 
E-Myc–only tumors (Fig. 6 A). Notably, BIM and PUMA levels 
were much higher in the leukemias in which BCL-2 or MCL-1 
was overexpressed. This suggests the possibility that the anti-
apoptotic buffering capacity permitted a more aggressive pheno-
type by fostering tolerance of greater level of pro-death signaling. 
The low levels of BIM and PUMA in the E-Myc–only tumors 
also supports the conjecture that there may be proteins that acti-
vate BAX and BAK and are sequestered by MCL-1 and BCL-2 
other than BIM and PUMA. Levels of BAX and BAK remained 
similar among all the samples, whereas levels of the sensitizer BAD 
greatly varied among the samples. Relative levels of Phospho-
Bad 112 mirrored total Bad levels (Fig. 6 B). There was very low 
signal detected using Phospho-Bad 136 (not depicted).
Leukemias that rely on MCL-1 for survival 
are more chemosensitive than those that 
rely on BCL-2
Although biochemical details are important in understanding 
leukemogenesis, it is of paramount practical clinical interest 
to understand how these changes affect response to chemo-
therapy. Although both MCL-1 and BCL-2 can cooperate with 
c-MYC to form leukemias, it has not been tested whether cel-
lular exploitation of one over the other might confer greater 
chemosensitivity. To put this question another way, with all 
other things being equal, do leukemia cells that depend on 
MCL-1 for survival have a different sensitivity to conventional 
chemotherapy agents than those that depend on BCL-2 for 
survival? To answer this question, we compared the sensitivity 
of our Mcl-1/E-Myc leukemia cell lines with those of our 
BCL-2/E-Myc  cell  lines  to  a  range  of  chemotherapeutic 
agents that work via diverse mechanisms (Fig. 7). The agents 
used included etoposide (topoisomerase II inhibitor), vincris-
tine (microtubule disruptor), staurosporine (broad spectrum 
other cell lines (Willis et al., 2005; Deng et al., 2007). Our results 
here do not rule out such interactions, but instead point out that 
many of the interactions between pro- and anti-apoptotic family 
proteins will be very dependent on the context, and specifically 
dependent on the abundance of other BCL-2 family proteins that 
might be competing as heterodimerization partners.
Heterogeneous dependence on BCL-2 and 
MCL-1 in lymphomas from E-Myc mice
Forced transgenic expression of BCL-2 and MCL-1 apparently 
buffers death signaling in a way that fosters the development of 
a MYC-driven leukemia that is more aggressive than the lym-
phoma that appears in E-Myc mice later in life. Yet even the 
less aggressive lymphomas in the E-Myc mice likely have 
death signals to buffer. It is unknown how E-Myc lymphomas 
block apoptosis. We asked whether the lymphomas in E-Myc 
mice also showed dependence on anti-apoptotic proteins, or 
whether they selected an alternative type of block in apoptosis 
(Deng et al., 2007). To answer this question, we turned again to 
Figure 4.  MCL-1 and BCL-2 are primed with BIM and PUMA in leukemia 
cells. (A) Coimmunoprecipiation of MCL-1 from CHAPS lysate of white 
blood cell primary sample or cell line from Mcl-1/E-Myc mouse. Blot was 
probed for BIM, PUMA, BID, BAX, BAK, and MCL-1. (B) Coimmunoprecipi-
ation of BCL-2 from CHAPS lysate of white blood cell primary sample or 
cell line from BCL-2/E-Myc mouse. Blot was probed for BIM, PUMA, BID, 
BAX, BAK, and BCL-2.435 MCL-1 and BCL-2 differ in chemoprotection • Brunelle et al.
We examined MCL-1 levels after treatment with vincris-
tine, etoposide, and flavopiridol and found that in each case 
MCL-1 levels were dramatically reduced over the first 24 h 
(Fig. 8, A–C), the time over which almost all cells were killed. 
In addition, it can be seen that the quicker MCL-1 levels were 
reduced, the more rapidly cells died. For instance, in cells 
treated with flavopiridol, MCL-1 levels were nearly undetect-
able at 8 h (Fig. 8 A) and nearly all cells were killed by 8 h   
(Fig. 9 B). Etoposide was next-most efficient at reducing MCL-1 
levels, followed by vincristine, again corresponding to how rap-
idly the cells were killed (Fig. 8, B and C; Fig. 9 B). Note that 
although the MCL-1 decrease for etoposide-treated 2640 cells 
appears modest, it was consistent, as demonstrated by densito-
metric analysis of four independent experiments. MCL-1 levels 
(average [standard deviation]) at 8, 16, and 24 h were 95% 
[18%], 76% [25%], and 72% [33%] of starting levels. In contrast, 
treatment with these same three agents had little effect on BCL-2 
levels in the BCL-2–dependent cell lines, with concomitantly 
slower killing kinetics and reduced toxicity to the drugs (Fig. 8, 
D–G; Fig. 9 C). It is important to note that although Mcl-1 lev-
els are driven by the H2K promoter in the Mcl-1/E-Myc mouse 
kinase inhibitor), flavopiridol (CDK9 inhibitor), fludarabine 
(purine analogue), MNNG (DNA alkylating agent), and bor-
tezomib and MG132 (proteosome inhibitors). We found that 
generally, Mcl-1/E-Myc leukemias were more sensitive to 
drug.  Comparison  of  treatment  with  MNNG,  vincristine, 
staurosporine, and etoposide all demonstrated differences be-
tween the MCL-1– and BCL-2–dependent leukemias with P value 
<0.05.  The  other  treatments  showed  differences  that  were 
close, but slightly above this level of statistical significance. 
These results suggested that when c-MYC leukemogenesis is 
facilitated by MCL-1, a more chemosensitive leukemia results 
than when it is facilitated by BCL-2.
MCL-1 levels decrease before commitment 
to death
Our BH3 profiling results showed that the leukemias are depen-
dent on continuous function of either MCL-1 or BCL-2 for sur-
vival. MCL-1 protein is known to have a much shorter half-life 
than BCL-2 (<1 h compared with 16–24 h) (Maurer et al., 2006). 
We  therefore  hypothesized  that  the  Mcl-1/E-Myc  leukemia 
lines might be more sensitive due to loss of MCL-1 protein.
Figure  5.  BH3  profiling  of  E-Myc  tumors 
reveals variable dependence on anti-apoptotic 
proteins. Data presented are from one single 
experiment.  (A)  E-Myc  tumor  #859  shows 
a MCL-1 profile. (B) E-Myc tumor #1107 
shows a profile where MCL-1 > BCL-2/BCL-XL.   
(C)  E-Myc  tumor  #1433  shows  a  profile 
where  MCL-1  >  BCL-2/BCL-XL.  (D)  E-Myc 
tumor #1656 shows a profile where BCL-2/
BCL-XL > MCL-1. (E) Western blot containing 
CHAPS lysates of the E-Myc tumors in order 
to compare protein levels of anti-apoptotic pro-
teins BCL-2, BCL-XL, and MCL-1. Note low BCL-2 
protein level in E-Myc tumor #859.JCB • VOLUME 187 • NUMBER 3 • 2009   436
important to distinguish whether MCL-1 loss occurs upstream or 
downstream of cellular death. To that end, it is important to note 
that the experiments in Fig. 8 were performed in the presence of 
the broad spectrum caspase inhibitor Q-VD-OPH, which was 
used at concentrations sufficient to inhibit manifestations of 
death including membrane permeabilization as measured by pro-
pidium iodide staining and phosphatidylserine exposure as mea-
sured by Annexin V staining (Fig. 9 A). Thus, MCL-1 loss is seen 
in the absence of overt manifestations of cell death, suggesting 
that MCL-1 loss is a cause, rather than a consequence, of cell 
death in these experiments.
MCL-1 protein half-life remains constant 
after treatment
Like all proteins, MCL-1 levels depend on an equilibrium be-
tween production and degradation. A decrease in MCL-1 can 
thus be due either to an increase in degradation or a decrease in 
production, or both. It has been shown that MCL-1 is subject to 
proteosomal degradation, both tonically and in response to 
numerous cellular perturbations (Nijhawan et al., 2003; Maurer   
et al., 2006). This can be seen here in the increase in MCL-1 
levels caused by treatment with the proteosome inhibitor bor-
tezomib (Fig. 8 A). Loss of MCL-1 after chemotherapy treatment 
could therefore be due to an induced increase in proteosomal 
degradation. To test whether degradation was increasing, we 
compared MCL-1 half-life in cells treated with cycloheximide 
in the presence and absence of flavopiridol, the drug that most 
rapidly caused MCL-1 loss. Fig. 10, A and B shows that the 
half-life is unaffected by flavopiridol, indicating that an increase 
in degradation is unlikely to play an important role in MCL-1 
loss. This suggests that the loss of MCL-1 after chemotherapy 
treatment in these leukemias is not due to an increase in its rate 
of degradation, but rather due to a decrease in its production 
caused by the toxic agents.
It has been found that NOXA can bind to MCL-1 and in-
crease the rate of proteosomal degradation of MCL-1 (Czabotar 
et al., 2007). Although our results here suggest that the rate of 
MCL-1 degradation is not increasing, we nonetheless tested 
whether changes in NOXA levels correlate to changes in MCL-1 
levels. We were unable to identify any antibody to recognize 
murine NOXA, so we used RT-PCR to quantitate NOXA mes-
sage levels. We found that although NOXA transcript levels in-
creased in response to bortezomib, etoposide, and vincristine, 
they decreased in response to flavopiridol (Fig. S2), where the 
most rapid MCL-1 decrease was seen. Thus, although we can-
not rule out a role for NOXA, an increase in NOXA transcript 
levels are not a requirement for MCL-1 loss.
MCL-1 and BCL-2 have similar a priori 
anti-apoptotic potency in the leukemias
The Mcl-1/ E-Myc and BCL-2/ E-Myc leukemias were con-
structed by the same basic method, and leukemias of identical 
morphology, cell surface phenotype, and clinical behavior were 
obtained. However, as the proteins were untagged, we could not 
directly compare absolute levels of BCL-2 and MCL-1. We 
could, however, test their relative “potency.” That is, we could 
test whether Mcl-1/E-Myc cells contained mitochondria that 
and MCL-1–dependent cell lines, endogenous levels of MCL-1 
are found in the BCL-2/E-Myc mouse and BCL-2–dependent 
cell lines. MCL-1 levels do decrease in the Bcl-2–dependent cells 
when treated with etoposide, vincristine, or flavopiridol (Fig. 8, 
E–G), suggesting that the changes in MCL-1 levels are not de-
pendent on the promoter from which protein expression derives.
After death, one might expect the levels of many short half-
life proteins to decrease, potentially including MCL-1. Thus, it is 
Figure 6.  Higher BIM and PUMA expression observed in MCL-1– and 
BCL-2–overexpressing leukemias. Western blot comparing protein levels 
among three E-Myc tumors, two BCL-2/E-Myc leukemias, and three Mcl-1/ 
E-Myc  leukemias.  (A)  The  proteins  blotted  were  MCL-1,  BCL-2,  BIM, 
PUMA, BID, BAD, BAX, and BAK. Please note that the BCL-2 transgene 
in the BCL-2/EMyc lymphomas is human. (B) The proteins blotted were 
BAD, Phospho-Bad (Ser112), and Actin.437 MCL-1 and BCL-2 differ in chemoprotection • Brunelle et al.
functional comparison that interrogates simultaneously the pos-
sible differential contribution of many BCL-2 family proteins in 
the two leukemias. In Fig. 10 C, we show that there is no signifi-
cant difference in the priming of Mcl-1/E-Myc and BCL-2/
E-Myc at the heavy membranes. In Fig. 10 D, we show a simi-
lar result using the whole-cell BH3 profiling technique. This 
implies that before treatment, the intrinsic sensitivity of the 
Mcl-1/E-Myc and BCL-2/E-Myc mitochondria to apoptotic 
were intrinsically more sensitive to apoptotic stimuli, even be-
fore perturbation with toxic agents. To test whether this was the 
case, we isolated mitochondria from Mcl-1/E-Myc and BCL-2/ 
E-Myc leukemia cell lines, and compared their response to the 
PUMA BH3 peptide. The PUMA BH3 peptide behaves as a 
sensitizer and interacts with all of the anti-apoptotic proteins 
(Certo et al., 2006). Thus, it can be used alone as an index of 
how primed for death a mitochondrion is. This test provides a 
Figure 7.  MCL-1–dependent leukemia lines are more sensitive to chemotherapy drugs than BCL-2–dependent leukemia lines. Dose response curves use the 
following drug treatments: MNNG, Vincristine, Staurosporin, Etoposide, MG132, Fludarabine, Flavopiridol, and Bortezomib. After 24 h of drug treatment, 
the cells were stained with Annexin/PI and the percentage of viable cells was graphed. Each time point is an average and standard deviation of three 
independent experiments. For the statistics, the three Mcl-1 cell lines and the three Bcl-2 cell lines were averaged and area under the curve was determined. 
P value was analyzed by using a paired t test of area under the curve.JCB • VOLUME 187 • NUMBER 3 • 2009   438
ARF/Mdm2/p53 pathway in a myc-driven lymphoma model 
(Schmitt et al., 2002).
In summary, we observed that MCL-1–dependent cancer 
cells were more sensitive to treatment with a range of chemo-
therapeutic agents than were matched BCL-2–dependent coun-
terparts. The mechanism behind the difference appears to be 
that MCL-1 is a short half-life protein subjected to ongoing 
proteosome-dependent degradation. Although the rate of this 
degradation does not change after chemotherapy treatment, 
chemotherapy apparently disrupts efficient MCL-1 protein pro-
duction, resulting in a rapid net loss of MCL-1 protein. BCL-2 
has a longer half-life and seems to be spared chronic proteo-
somal degradation, so its levels are relatively stable after treat-
ments, resulting in less chemosensitivity.
Discussion
Here we report a comparison of murine models of MCL-1– and 
BCL-2–dependent lymphoid leukemias. MCL-1 dependence 
has not been previously demonstrated in a murine cancer model. 
We now have a system of cell lines and murine leukemia models 
that are apparently identical except for their different dependence 
signaling is the same. This is consistent with the hypothesis that 
net loss of MCL-1 after drug treatment is responsible for the se-
lective sensitivity of the MCL-1–dependent leukemias.
Our data suggest that Mcl-1–dependent cells are killed 
easier than those that are Bcl-2 dependent, all other things 
being equal. However, the ARF/Mdm2/p53 pathway can also 
play an important role in apoptosis, and it has previously been 
found that selection of alterations of this pathway can be   
altered by anti-apoptotic protein expression in a myc-driven 
lymphoma model (Schmitt et al., 2002). We measured expres-
sion of ARF and p53 to test whether MCL-1 expression sys-
tematically  resulted  in  a  different  proportion  of  p53-  or 
ARF-overexpressing  tumors  compared  with  BCL-2  expres-
sion. In Fig. S3, we show that MCL-1 and BCL-2 expression 
result in similar proportions of p53 and ARF up-regulation 
(6/12 vs. 7/12, 5/12 vs. 5/12, respectively). Note that p53 up-
regulation, indicating a defect in the ARF/Mdm2/p53 tumor 
suppressor pathway, was found in 10 of 11 E-Myc samples 
tested,  a  higher  proportion  than  was  reported  previously 
(Eischen et al., 1999). These results are consistent with prior 
results which found that forced expression of an anti-apoptotic 
protein decreased the rate of selection for abnormalities in the 
Figure  8.  Varied  chemotherapeutics  induce  MCL-1   
before cell death. All cell lines pretreated with 20 M 
of  caspase  inhibitor  Q-VD-OPH  for  1  h.  CHAPS 
lysates were prepared and MCL-1, BCL-2, BIM, and 
Actin protein levels were determined using Western 
blotting. (A) Mcl-1/E-Myc cell lines treated with 1 M 
Bortezomib or 1 M Flavopiridol for 0, 8, and 16 h. 
(B) Mcl-1/E-Myc cell lines treated with 1 M Etopo-
side for 0, 8, 16, and 24 h. (C) Mcl-1/E-Myc cell 
lines treated with 1 M Vincristine for 0, 8, 16, and 
24 h. (D and E) BCL-2/E-Myc cell lines treated with 
1 M Etoposide or 1 M Vincristine for 0, 8, 16, and 
24 h. (F) BCL-2/E-Myc cell lines treated with 1 M   
Bortezomib for 0, 8, and 16 h. (G) BCL-2/E-Myc cell 
lines treated with 1 M Flavopiridol for 0, 8, and 16 h.439 MCL-1 and BCL-2 differ in chemoprotection • Brunelle et al.
on either BCL-2 or MCL-1. Such a system has potential utility 
as in vivo and in vitro test systems for putative selective antago-
nists of either BCL-2 or MCL-1 that are currently in preclinical 
and clinical development for cancer therapy. In addition, as we 
have exploited it in this paper, such a system is useful in under-
standing the mechanisms by which cancer cells escape apoptosis, 
and in comparing the similarities and differences in biological 
function between BCL-2 and MCL-1.
We have previously reported testing BH3 profiling in 
model systems in which BH3 profiling accurately identified   
Figure 9.  The Mcl-1/E-Myc cell line dies faster than the BCL-2/E-Myc 
cell line. (A) Annexin/PI measurement used to determine cell viability of 
Mcl-1/E-Myc  cell  line  using  Etoposide,  Flavopiridol,  Vincristine,  and 
DMSO drug treatments with and without 20 M Q-VD-OPH. Data pre-
sented are an average and standard deviation of three independent ex-
periments. (B) Dose-response curve of Mcl-1/E-Myc cell line treated with 
1 M of Etoposide, Flavopiridol, or Vincristine over 8, 16, 24, and 48 h.   
Data presented are an average and standard deviation of three inde-
pendent experiments. (C) Dose-response curve of BCL-2/E-Myc cell line 
treated with 1 M Etoposide, Flavopiridol, or Vincristine over 8, 16, 24, 
and 48 h. Data presented are an average and standard deviation of three 
independent experiments.
dependence on different individual anti-apoptotic proteins, but 
have not previously identified a purely MCL-1–dependent cancer. 
Here we find that BH3 profiling could usefully validate the 
Figure 10.  MCL-1 half-life is unchanged by flavopiridol treatment; MCL-1–   
and BCL-2–dependent mitochondria demonstrate equivalent pretreat-
ment “priming.” (A) A Mcl-1/E-Myc cell line pretreated with 20 M of 
caspase inhibitor Q-VD-OPH for 1 h, followed by treatment with 20 M 
cycloheximide (CHX). CHAPS lysates were made after each hour of treat-
ment. (B) A Mcl-1/E-Myc cell line pretreated with 20 M of caspase 
inhibitor Q-VD-OPH for 1 h, followed by a combined treatment with 20 M 
cycloheximide (CHX) and 1 M Flavopiridol. CHAPS lysates were made 
after each hour of treatment. (C) BH3 profiling of a Mcl-1/E-Myc and 
BCL-2/E-Myc cell line using decreasing concentrations of the PUMA pep-
tide. BAD and NOXA peptides were included as controls. Three indepen-
dent experiments were averaged. (D) BH3 profiling by the whole-cell JC1 
method at the 60-min time point. The results of the three Bcl-2 cell lines and 
three Mcl-1 cell lines were averaged for the following peptides: Puma, 
Bad, Noxa25, and FCCP.JCB • VOLUME 187 • NUMBER 3 • 2009   440
still poorly understood for individual tumors. Yet it is important 
to understand chemosensitivity because this is a necessary, though 
not sufficient, condition for cure by chemotherapy.
Chemosensitivity of the E-myc and E-myc/E-BCL-2 
leukemia/lymphoma models was compared in a recent manu-
script (Mason et al., 2008). In contrast with our BCL-2/E-Myc 
model, the expression of BIM in the E-myc/E-BCL-2 can-
cers was similar to that in the E-myc cancers. Consistent with 
our expectation that tumors from the E-myc model would be 
more frequently MCL-1 dependent (see Fig. 5), MCL-1 levels 
were higher in these malignancies than in the E-myc/E-BCL-2 
malignancies. Both models were subjected to treatment with 
cyclophosphamide, an alkylating agent. Consistent with our 
findings that E-myc tumors are frequently MCL-1 dependent, 
and the leukemias based on myc and BCL-2 transgenes BCL-2 
dependent, and that MCL-1–dependent tumors tend to respond 
better to chemotherapy, the E-myc mice demonstrated vastly 
superior survival after therapy, with a 50% long-term survival 
compared with 0% in the E-myc/E-BCL-2 mice. These re-
sults support an in vivo drug sensitivity consequence to MCL-1 
dependence versus BCL-2 dependence in cancers.
It may well be that using BH3 profiling or other strategies, 
other tumors, perhaps even primary tumors, will be revealed as 
MCL-1 dependent. Indeed, there is already reason to believe that 
many myeloma cells may be MCL-1 dependent (Derenne et al., 
2002). Superficially, our results may suggest that such cells will 
be readily killed by a wide variety of agents. More exactly 
stated, however, our prior results and those here suggest that 
primed cells that are dependent on any anti-apoptotic protein 
will be killed easier that unprimed, and that primed cells that are 
MCL-1 dependent will be killed easier that those that are BCL-2 
dependent, all other factors being equal. Achieving comparisons 
where all other factors are equal, outside of purposefully con-
structed models, will indeed be difficult, but perhaps with suffi-
cient numbers, informative testing of the hypothesis may be 
possible. It will be interesting to test this hypothesis in the com-
ing years as relevant cancers are identified. However, we already 
know that our use of cytotoxic drugs is limited by toxicity, so 
that more directly targeted therapy may be superior. Thus, selec-
tive antagonists of MCL-1 may eventually play an important role 
in treating MCL-1–dependent cancers.
A key generalizable finding of this study is that the type 
of block in apoptosis selected by a cancer during tumorigene-
sis can significantly influence chemosensitivity. Though two 
different anti-apoptotic proteins might both enable leukemo-
genesis, the leukemias derived differ critically in their chemo-
sensitivity. As shown here and previously, BH3 profiling can 
identify types of blocks in apoptosis, and thus may be useful 
in prediction of chemosensitivity.
Materials and methods
Transgenic mice
The MMTV-tTA/tet-BCL-2/E-Myc mouse has been described previously 
(Letai et al., 2004).
Mcl-1 transgenic mice
A minigene containing the H2K promoter/enhancer and the Moloney 
MuLV enhancer/poly(A) site (a gift from Dr. Jos Domen, Medical College 
distinction between MCL-1 and BCL-2 dependence in leuke-
mia models based on MCL-1 or BCL-2 overexpression in com-
bination with the E-Myc transgene. However, the E-Myc 
transgene by itself drives formation of lymphomas, leading us 
to ask how these tumors escaped apoptosis. Although the E-Myc 
lymphoma model has been studied for decades, the tools were 
not previously available to investigate its dependence on anti-
apoptotic proteins (Adams et al., 1985). Using BH3 profiling, 
we find that in the absence of forced overexpression of any sin-
gle anti-apoptotic protein, E-Myc lymphomas are nonetheless 
dependent on anti-apoptotic proteins for survival. The specific 
anti-apoptotic protein dependence varies from lymphoma to 
lymphoma, and can be mixed in a single lymphoma. The source 
for the differences may lie in a simple stochastic selection for 
greater or lesser expression of one or the other of the anti-
apoptotic proteins, as seems to be the case for lymphoma #859 
(Fig. 5). Alternatively, the differences in expression may reside 
in inherent differences in differing initiating cells selected for 
tumorigenesis in each animal.
We also asked if the anti-apoptotic proteins in our leuke-
mias  are  primed,  what  pro-death  molecules  are  they  primed 
with? We were unable to observe sequestration of BAX or BAK 
in our leukemias. Instead, we observed sequestration of the pro-
death BH3-only proteins BIM and PUMA. This observation is 
more consistent with a model in which the most important anti-
apoptotic function of anti-apoptotic proteins like BCL-2 or 
MCL-1 is to sequester BH3-only proteins (Cheng et al., 1996; 
Cheng et al., 2001; Letai et al., 2002; Kuwana et al., 2005; Certo 
et al., 2006). The pure indirect model would suggest that we 
should have observed sequestration of BAX and BAK. Although 
we observed sequestration of both BIM and PUMA, it is yet pos-
sible that in these leukemias BCL-2 and MCL-1 sequester other 
BH3-only proteins, perhaps some not yet even identified as 
BH3-only proteins. If indeed the sequestration of BIM or PUMA 
is critical to the function of MCL-1 or BCL-2, one would expect 
that loss of PUMA or BIM might also be able to cooperate with 
E-Myc to drive development of the less mature leukemias. In 
fact, loss of PUMA or BIM combined with the E-Myc trans-
gene does cause development of the immature leukemia, sup-
porting their sequestration as a key role performed by MCL-1 
and BCL-2 (Egle et al., 2004; Michalak et al., 2009).
Despite the similarity in phenotype and in biochemical 
properties,  the  BCL-2/E-Myc  and  Mcl-1/E-Myc  leukemias 
differed consistently in their sensitivity to cytotoxic agents. Our 
results suggest that this is because proteosomal degradation of 
MCL-1 persists while new synthesis of MCL-1 is reduced by 
treatment with a wide variety of agents. This changes the steady 
state so that there is a net loss of MCL-1, resulting in accelerated 
death of MCL-1–dependent cells. A similar observation has   
been made in the response of HeLa cells to ultraviolet radiation   
(Nijhawan et al., 2003). Here, we show that MCL-1 loss is a more 
general phenomenon following a wide variety of insults. Such a 
net loss does not occur for the longer half-life BCL-2 protein, 
which is more stable. Killing the BCL-2–dependent cells thus 
requires more time and more drug (Figs. 7 and 9). Note that our 
studies cannot address issues of which tumors are cured because 
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reader, and the fluorescence at 590 nM monitored every 5 min at ambi-
ent temperature.
Westerns and coIPs
MCL-1 IP. White blood cells isolated from Mcl-1/E-Myc mice were put in 
1% CHAPS lysis buffer. MCL-1 antibody (3 g; Rockland) was added to 
50 g of lysate and incubated on a rotator for at least 1 h at 4 degrees. 
Control antibody used for IPs was MnSOD (SOD-111; Stressgen). Protein 
A beads (Sigma-Aldrich) were subsequently added and the resulting mix-
ture was incubated for another hour. Beads were washed three times with 
CHAPS  lysis  buffer  and  then  loading  dye  was  added.  Samples  were 
heated and then run on a 10% gel.
BCL-2  IP.  White  blood  cells  isolated  from  BCL-2/E-Myc  mice 
were put in 1% CHAPS lysis buffer. BCL-2 6C8 (551051; BD) antibody 
(3 g) was added to 10 g of lysate and incubated on a rotator for at 
least  1  h  at  4  degrees.  Control  antibody  used  for  IP’s  was  CD40 
(553721; BD). Protein A/G beads (Santa Cruz Biotechnology, Inc.) 
were subsequently added and the resulting mixture was incubated for 
another hour. Beads were washed three times with CHAPS lysis buffer 
and then loading dye was added. Samples were heated and then run 
on a 10% gel.
Antibodies  used  in  Western  blots  were:  Actin  (Millipore),  Mcl-1 
(Rockland), Human Bcl-2/100 (BD), Mouse Bcl-2 3F11 (BD), Bcl-XL (pro-
vided by Larry Boise, Emory University, Atlanta, GA), BIM 22–40 (EMD), 
BID (Santa Cruz Biotechnology, Inc.), BAD (Santa Cruz Biotechnology, 
Inc.), Phospho-Bad Ser112 (Cell Signaling Technology), BAX N20 (Santa 
Cruz  Biotechnology,  Inc.),  BAK  NT  (Millipore),  PUMA  (Sigma-Aldrich), 
p53 (EMD), and p19ARF (Abcam). Secondary antibody used for coIPs 
was Protein A HRP linked (GE Healthcare). Secondary antibodies for all 
other blots were anti–mouse HRP linked (GE Healthcare), anti–rabbit HRP 
linked (GE Healthcare), anti–hamster HRP linked (Jackson ImmunoResearch 
Laboratories, Inc.), and anti–rat HRP linked (GE Healthcare).
Imaging was performed using Super Signal chemiluminescence de-
veloping agent (Thermo Fisher Scientific) either onto film or using an Image 
Reader (model LAS-4000; Fujifilm).
RT-PCR
RNA was isolated using Trizol (Invitrogen) and the Promega Access RT-
PCR System was used to determine levels of Noxa and GAPDH. Noxa 
primers were forward: CGTCGGAACGCGCCAGTGAACCC and reverse: 
TCCTTCCTGGGAGGTCCCTTCTTGC.  GAPDH  primers  were  forward:   
TGATGACATCAAGAAGGTGGTGAAG and reverse: TCCTTGGAGGCC-
ATGTAGGCCAT.
Drugs
Drugs are as follows: MNNG (Thermo Fisher Scientific), Vincristine (Sigma-
Aldrich), Staurosporin (Sigma-Aldrich), Etoposide (Sigma-Aldrich), MG132 
(Sigma-Aldrich),  Fludarabine  (Sigma-Aldrich),  Flavopiridol  (Alexis  Bio-
chemicals), and Bortezomib (LC Laboratories).
Online supplemental material
Fig. S1: the whole-cell method of BH3 profiling. Fig. S2: Noxa mRNA levels 
after drug treatment. Fig.S3: protein levels of p53 and ARF in BCL-2/Eµ-Myc, 
Mcl-1/E-Myc, and E-Myc samples. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200904049/DC1.
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of Wisconsin, Milwaukee, WI) driving the expression of mouse Mcl-1 
cDNA  was  injected  into  zygotes  obtained  from  crosses  between  F1 
(C57BL/6 3 C3H) mice. Resulting progeny were tested by Southern blot-
ting, and positive mice were backcrossed to C57BL/6 mice. Four inde-
pendent founder lines were generated with different expression levels as 
tested by Western blot. The transgenic mice were generated, housed, and 
bred in the Dana-Farber Cancer Institute (DFCI) animal facility. All animal 
experiments were approved by the Dana-Farber Cancer Institute IACUC 
(protocol #05-001).
Mice  containing  the  H2K-Mcl-1  transgene  (usually  female)  were 
bred to E-Myc mice (usually male).
Monitoring leukemia
Blood from a razor nick was diluted in buffer (saponin 0.3%, Hoechst 
33258 1 g/ml, EDTA 25 mM in PBS) and manual counts of white blood 
cells were performed.
Pathology
Spleen and bone marrow samples were stored in formalin and sent to the 
Dana Farber Harvard Cancer Center Pathology Core for processing with 
hematoxylin and eosin stain.
Microscopy and image analysis
The microscope used was a Nikon Eclipse E600. To view the bone marrow 
samples the objective lens was a Nikon Plan Fluor 20x/0.75 NA. To view 
the spleen samples the objective lens was a Nikon Plan Fluor 10x/0.30 NA. 
The camera was a SPOT RT SE from Diagnostic Instruments, Inc. (model 
9.0 monochrome-6) with SPOT software for image acquisition.
Mouse cell lines
White  blood  cells  were  isolated  from  blood  using  Ficoll  gradient. 
Spleens were removed from the mouse and smashed between two glass 
slides. Smashed spleens and white blood cells were placed in 50 mL of 
RPMI,  10%  FBS,  1%  PenStrep,  and  -mercaptoethanol.  Media  was 
changed 2–3 times per wk. After approximately 3 wk, cell mixture was 
split 1:2. As population of dividing cells emerged, cells were split 1:5 
as necessary.
BH3 profiling using heavy membranes
Mitochondria were isolated from the white blood cells of Mcl-1/E-Myc 
or BCL-2/E-Myc mice, E-Myc lymphomas, or cell lines. In brief, cells 
were placed in isolation buffer (250 mM sucrose, 10 mM Tris-HCL, pH 7.4, 
and 0.1 mM EGTA) and cell disruption was performed with several 
passes through a 27-gauge needle. After the sample was centrifuged at 
600 g for 10 min, the resulting supernatant was centrifuged at 10,000 g 
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